Amedeo Smart

Free Medical Literature Service


 

Amedeo

Liver Diseases

  Free Subscription

27.10.2025

1 Am J Gastroenterol
1 Am J Pathol
3 BMC Cancer
3 BMC Gastroenterol
2 Dig Dis Sci
3 Endoscopy
2 Eur Radiol
1 Gastroenterology
1 Gastrointest Endosc
1 Gut
4 Hepatology
2 Indian J Gastroenterol
3 Int J Cancer
3 J Gastroenterol
1 J Gastroenterol Hepatol
12 J Hepatol
2 Lancet
1 Minerva Gastroenterol (Torino)
3 PLoS One
1 Proc Natl Acad Sci U S A
1 Radiology
3 Transplantation



    Am J Gastroenterol

  1. DE FARIA MORAES B, Pedral Diniz Leite GA, Pedral Diniz Leite GA, Motta Fonseca ML, et al
    Reevaluating the Role of Proton Pump Inhibitors After Endoscopic Band Ligation of Esophageal Varices in Cirrhotic Patients: A Systematic Review and Meta-analysis.
    Am J Gastroenterol. 2025 Oct 21. doi: 10.14309/ajg.0000000000003800.
    >> Share


    Am J Pathol

  2. CACERES A, Shibata NM, Davalos-Gutierrez CD, Sarode GV, et al
    Inactivation of Atp7b copper transporter in intestinal epithelial cells is associated with altered lipid processing and cell growth machinery independent from hepatic copper accumulation and severity of liver histology.
    Am J Pathol. 2025 Oct 16:S0002-9440(25)00379.
    >> Share


    BMC Cancer

  3. NONG X, Yao Y, Xie J, Liang J, et al
    Preliminary experience of lenvatinib, tislelizumab and transcatheter arterial chemoembolization for BCLC stage C hepatocellular carcinoma: a phase II study.
    BMC Cancer. 2025;25:1631.
    >> Share

  4. LUO Y, Zhang G, Zhong S, Chen S, et al
    Deep multi-instance learning model based on gadoxetic acid-enhanced MRI for predicting microvascular invasion of hepatocellular carcinoma: a multicenter, retrospective study.
    BMC Cancer. 2025;25:1626.
    >> Share

  5. HOU S, Hu S, Wu Q, Sun H, et al
    Efficacy and safety of stereotactic body radiation therapy combined with targeted agents and immunotherapies in hepatocellular carcinoma: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:1602.
    >> Share


    BMC Gastroenterol

  6. ELSABAAWY M, Afify S, Othman W, Ragab A, et al
    Frailty and liver transplant eligibility beyond MELD scores: integrating functional status into candidate selection.
    BMC Gastroenterol. 2025;25:743.
    >> Share

  7. AGHAZADEH MH, Azizmohammad Looha M, Khaleghjoo Y, Ghoorchi Beigi F, et al
    Mortality risk prediction in liver transplant candidates: a prognostic model using key clinical variables.
    BMC Gastroenterol. 2025;25:745.
    >> Share

  8. YANG X, Wang G, Gao L, Chen J, et al
    Lactate-to-glucose ratio and short-term all-cause mortality in critically ill cirrhosis patients: a MIMIC-IV and eICU-CRD database study.
    BMC Gastroenterol. 2025;25:750.
    >> Share


    Dig Dis Sci

  9. BHATI G, Bhati K, Gupta A, Bansal R, et al
    Hitting the Nail on the Head: A Laparoscopic Retrieval of a Metallic Intrahepatic Foreign Body.
    Dig Dis Sci. 2025 Oct 22. doi: 10.1007/s10620-025-09477.
    >> Share

  10. ISMAIL A, Abusuliman M, Kloub M, Abbarh S, et al
    Comparative Risk of Recurrent Esophageal Variceal Hemorrhage and Other Decompensation Events with Carvedilol Versus Propranolol in Patients with Cirrhosis: A Retrospective Study.
    Dig Dis Sci. 2025 Oct 18. doi: 10.1007/s10620-025-09453.
    >> Share


    Endoscopy

  11. YAMAMOTO K, Tsuchiya T, Tonozuka R, Mukai S, et al
    Endoluminal radiofrequency ablation for ingrowth occlusion after endoscopic ultrasound-guided hepaticogastrostomy with bridging stent placement.
    Endoscopy. 2025;57.
    >> Share

  12. ZHANG W, Zhang L, Hou S
    Management of short-term recurrent obstructive jaundice after endoscopic ultrasound guided hepaticogastrostomy.
    Endoscopy. 2025;57.
    >> Share

  13. BAN T, Kubota Y, Hirayama Y, Ando K, et al
    Multi-holed fully covered self-expandable metal stent to dilate a benign hepaticojejunostomy anastomotic stricture.
    Endoscopy. 2025;57.
    >> Share


    Eur Radiol

  14. CHIU SH, Kamaya A, Tse JR
    Letter to the Editor: Early post-treatment imaging enables timely diagnosis of viable hepatocellular carcinomas after selective internal radiation therapy.
    Eur Radiol. 2025 Oct 17. doi: 10.1007/s00330-025-11998.
    >> Share

  15. WEI H, Jiang H, Lee JM
    Reply to the Letter to the Editor: Early post-treatment imaging enables timely diagnosis of viable hepatocellular carcinomas after selective internal radiation therapy.
    Eur Radiol. 2025 Oct 17. doi: 10.1007/s00330-025-11999.
    >> Share


    Gastroenterology

  16. ORMAN ES, Fortune BE, John BV, Asrani SK, et al
    AGA Clinical Practice Update on the Management of Ascites, Volume Overload, and Hyponatremia in Cirrhosis: Expert Review.
    Gastroenterology. 2025 Oct 20:S0016-5085(25)05959.
    >> Share


    Gastrointest Endosc

  17. TAKASAKI Y, Isayama H, Yamaguchi Y, Hagiwara H, et al
    Peroral cholangioscopy-guided laser-stricturoplasty for intrahepatic benign biliary strictures (with video).
    Gastrointest Endosc. 2025 Oct 18:S0016-5107(25)02113.
    >> Share


    Gut

  18. YANG Z, Hu Y, Yang C, Li Y, et al
    SMYD2-mediated methylation of STAT1 protects against hepatic ischaemia/reperfusion injury by blocking JAK-STAT1 signalling pathways.
    Gut. 2025 Oct 17:gutjnl-2025-336400. doi: 10.1136/gutjnl-2025-336400.
    >> Share


    Hepatology

  19. WALIA N, Hui S, Braude M
    Letter to the Editor: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD.
    Hepatology. 2025 Oct 23. doi: 10.1097/HEP.0000000000001586.
    >> Share

  20. GRIMAUD E, Gardin A, Ackermann O, Habes D, et al
    Serum bile acid levels predict the development of portal hypertension and high-risk esophageal varices following successful Kasai in biliary atresia.
    Hepatology. 2025 Oct 23. doi: 10.1097/HEP.0000000000001592.
    >> Share

  21. DELGADO ER, Patel P, Tao J, Krutsenko Y, et al
    Glutamine synthetase loss in beta-catenin-mutant hepatocellular carcinoma promotes tumor burden through macrophage metabolic reprogramming.
    Hepatology. 2025 Oct 23. doi: 10.1097/HEP.0000000000001591.
    >> Share

  22. JOHN BV, Bastaich D, Singal AG, Dahman B, et al
    Reply: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD.
    Hepatology. 2025 Oct 20. doi: 10.1097/HEP.0000000000001587.
    >> Share


    Indian J Gastroenterol

  23. JAIN M
    Comment on "Child-Turcotte-Pugh score-based modified anti-tubercular treatment in patients with decompensated cirrhosis with tuberculosis: A two-year retrospective observational study from North India".
    Indian J Gastroenterol. 2025 Oct 23. doi: 10.1007/s12664-025-01898.
    >> Share

  24. ALEXANDER V, John A, Benjamin S, Akilesh S, et al
    Non-selective beta blockers are well tolerated in pregnancy with portal hypertension.
    Indian J Gastroenterol. 2025 Oct 23. doi: 10.1007/s12664-025-01876.
    >> Share


    Int J Cancer

  25. ZHENG Y, Han J, Qu Y, Wang J, et al
    Circulating cell-free DNA methylation biomarkers for hepatocellular carcinoma risk prediction in HIV-positive Nigerian population.
    Int J Cancer. 2025 Oct 23. doi: 10.1002/ijc.70204.
    >> Share

  26. DE SALINS V, Martinez-Tapia C, Gay P, Morel A, et al
    The Fibrosis-4 score is associated with overall mortality and severe haematological toxicity in older patients with cancer: Analysis of two prospective cohort studies.
    Int J Cancer. 2025;157:2506-2520.
    >> Share

  27. LI H, Feng Y, Wang Z, Li X, et al
    Advances in the management of ovarian cancer liver metastasis.
    Int J Cancer. 2025 Aug 16. doi: 10.1002/ijc.70065.
    >> Share


    J Gastroenterol

  28. HINO K, Nishina S, Yanatori I
    Ferroptosis: biology and role in liver disease.
    J Gastroenterol. 2025;60:1339-1361.
    >> Share

  29. TAKEMURA Y, Ueda Y, Takemura R, Mita J, et al
    Current status of waitlist mortality and transplant probability for adult candidates with chronic end-stage liver disease for deceased donor liver transplantation under the Model for End-Stage Liver Disease score-based allocation policy in Japan.
    J Gastroenterol. 2025;60:1414-1426.
    >> Share

  30. IWASA T, Miwa T, Utakata Y, Oi M, et al
    Development of overt hepatic encephalopathy increases mortality in patients with cirrhosis: a multicenter retrospective cohort study.
    J Gastroenterol. 2025 Oct 17. doi: 10.1007/s00535-025-02309.
    >> Share


    J Gastroenterol Hepatol

  31. FAN C, He X, Zhou Y, Ye C, et al
    The Effects of CD100 Stimulation on Primary Human Hepatocytes (PHHs) and Its Implications in HBV-Related Liver Cirrhosis.
    J Gastroenterol Hepatol. 2025 Oct 21. doi: 10.1111/jgh.70123.
    >> Share


    J Hepatol

  32. YUAN H, Zhao L, Yang G, Zhang S, et al
    HBx-induced HSPB1 is a potential therapeutic target owing to its modulation of HBV cccDNA and hepatic immune responses.
    J Hepatol. 2025 Oct 16:S0168-8278(25)02556-5. doi: 10.1016/j.jhep.2025.
    >> Share

  33. CELSA C, Pinato DJ, Cabibbo G
    "Advancing Clinical Trial Design and Patient Care in Hepatocellular Carcinoma".
    J Hepatol. 2025 Oct 17:S0168-8278(25)02558-9. doi: 10.1016/j.jhep.2025.
    >> Share

  34. GLYNN AM, Faye MD, Gerard IJ, Vanner RJ, et al
    Stereotactic body radiotherapy treatment for hepatocellular carcinoma with extensive macrovascular invasion.
    J Hepatol. 2025 Oct 17:S0168-8278(25)02559-0. doi: 10.1016/j.jhep.2025.
    >> Share

  35. VAZ J, Nasr P, Helander A, Shang Y, et al
    Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes.
    J Hepatol. 2025;83:1011-1022.
    >> Share

  36. GHALLAB A, Mandorfer M, Stirnimann G, Geyer J, et al
    Enteronephrohepatic Circulation of Bile Acids and Therapeutic Potential of Systemic Bile Acid Transporter Inhibitors.
    J Hepatol. 2025 May 23:S0168-8278(25)02207-X. doi: 10.1016/j.jhep.2025.
    >> Share

  37. LIU J, Xiao S, Hu S, Huang R, et al
    Dissecting metabolic dysfunction- and alcohol-associated liver disease (MetALD) using proteomic and metabolomic profiles.
    J Hepatol. 2025;83:1035-1045.
    >> Share

  38. ALGUERO-NADAL A, Mol H, Zoppolato E, Kowalczyk W, et al
    Steatotic liver disease induces YAP/TAZ-driven cell competition that can suppress tumor initiation.
    J Hepatol. 2025;83:1142-1155.
    >> Share

  39. TAVAGLIONE F, Diaz LA, Ajmera V, Madamba E, et al
    Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification.
    J Hepatol. 2025;83:1023-1034.
    >> Share

  40. JAECKEL E, Friedman SL, Hudecek M, Protzer U, et al
    Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseases.
    J Hepatol. 2025;83:1156-1171.
    >> Share

  41. BEUERS U, Banales JM, Karpen S, Keitel V, et al
    History and prospects of bile acid therapies.
    J Hepatol. 2025 Jun 20:S0168-8278(25)02277-9. doi: 10.1016/j.jhep.2025.
    >> Share

  42. PU X, Liu Y, Lyu Z, Zhou Y, et al
    B cells drive CCR5(+)CD4(+) tissue-resident memory T cell cytotoxicity via IL-15Ralpha-IL-15 signaling in primary biliary cholangitis.
    J Hepatol. 2025 Jul 17:S0168-8278(25)02340-2. doi: 10.1016/j.jhep.2025.
    >> Share

  43. TORP N, Israelsen M, Thiele M, Rinella ME, et al
    Phosphatidylethanol in steatotic liver disease.
    J Hepatol. 2025;83:1189-1203.
    >> Share


    Lancet

  44. KASEB A, Pawlik TM
    Perioperative camrelizumab plus rivoceranib versus surgery in resectable hepatocellular carcinoma.
    Lancet. 2025 Oct 19:S0140-6736(25)02104-X. doi: 10.1016/S0140-6736(25)02104.
    >> Share

  45. WANG Z, Fan J, Zhou S, Sun Y, et al
    Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.
    Lancet. 2025 Oct 19:S0140-6736(25)01720-9. doi: 10.1016/S0140-6736(25)01720.
    >> Share


    Minerva Gastroenterol (Torino)

  46. TEJEDOR-TEJADA J, Hermida B, Camblor C, Robles S, et al
    Timing of endoscopy in cirrhotic patients with acute variceal bleeding: a multicenter cohort study.
    Minerva Gastroenterol (Torino). 2025 Oct 21. doi: 10.23736/S2724-5985.25.03930.
    >> Share


    PLoS One

  47. HAMAD RS, Elshaer MAA, El-Mahdy HA, Mohammed OA, et al
    Green-synthesized zinc oxide nanoparticles using Echinops spinosus extract: A promising anticancer agent for hepatocellular carcinoma.
    PLoS One. 2025;20:e0331171.
    >> Share

  48. HUANG A, Su M, Zhang S, Zhao C, et al
    Alterations in the gut microbiota of alcoholic cirrhosis patients infected with Clonorchis sinensis in the Pearl River Delta region of China.
    PLoS One. 2025;20:e0334311.
    >> Share

  49. ONO Y, Sakai K, Okamura T, Okada H, et al
    Metabolic dysfunction-associated steatotic liver disease (MASLD) can be a possible predictive factor of incident CKD: NAGALA cohort study.
    PLoS One. 2025;20:e0334720.
    >> Share


    Proc Natl Acad Sci U S A

  50. GU L, Du Y, Nazmul Hasan M, Clayton YD, et al
    Adipose cullin 3 mediates the antiobesity effect of pan neddylation inhibitors.
    Proc Natl Acad Sci U S A. 2025;122:e2515947122.
    >> Share


    Radiology

  51. DENG M, Li Z, Sun L, Wang H, et al
    Liver MRI-derived Proton Density Fat Fraction Predicts Diabetes Risk in Patients with Obesity: A Dose-Response Study.
    Radiology. 2025;317:e250026.
    >> Share


    Transplantation

  52. WALLER D, Chinnakotla S, Ramanathan K, Brierton J, et al
    Liver Retransplantation: Identifying Factors and Developing a Risk Prediction Model to Predict Futility in the Modern Era.
    Transplantation. 2025;109:1765-1773.
    >> Share

  53. LIU JY, Liao W, Chen ZY, Liu T, et al
    PKM2 Drives Lactate-mediated Fibrosis in Liver Transplantation.
    Transplantation. 2025 Jun 27. doi: 10.1097/TP.0000000000005461.
    >> Share

  54. KARLINSKI VIZENTIN V, Antunes V, Ferreira Felix I, Florencio de Mesquita C, et al
    Combined Heart and Liver Transplantation in the Failing Fontan: Systematic Review and Single-arm Meta-analysis.
    Transplantation. 2025 May 5. doi: 10.1097/TP.0000000000005400.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016